APEIRON Biologic's work on a drug candidate against COVID-19
Read more
Improving the life of our patients with next-generation technologies and individual therapies About UsContact Us Improving the life of our patients with next-generation technologies and individual therapies About UsContact Us

APEIRON Biologics at a glance

  • First Austrian biotech company to develop a cancer immunotherapy product through to market
  • Approval in 2017 for treatment of pediatric neuroblastoma in EU and other countries, US/Japan BLA filing in preparation
  • Respiratory drug candidate APN01 in clinical development
  • Oncology pipeline in clinical stages
  • Focused on novel cancer immunotherapies and respiratory treatments
  • Lead by highly experienced and motivated team with global background

NEWS

APEIRON Biologics AG strengthens shareholder structure and Supervisory Board with international anchor investor
- British investor consortium Franklin Road Ltd. increases its stake in APEIRON Biologics significantly to over 13% - Extraordinary General Meeting elects Edward Charles MA, Managing Director of Franklin Road Ltd., as a new Supervisory Board member Press release (EN) | Presseaussendung (DE)
October 15, 2020
THE LANCET publishes promising data of APEIRON’s APN01 (rhsACE2) to treat COVID-19 in named patient use
- Case study from promising first COVID-19 patient treatment with APN01 supports APEIRON’s ongoing pivotal Phase II clinical trial - First data on the effect of blocking the spike protein in COVID-19 patient confirm mode of action of APN01 specifically targeting SARS-CoV-2 Press release (EN) | Presseaussendung (DE)
September 25, 2020
APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401
APEIRON to utilize MaxCyte’s ExPERT® platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming clinical trials. Press release (EN) | Presseaussendung (DE)
July 8, 2020